We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

73 hedge funds and large institutions have $244M invested in KalVista Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 14

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

60% more capital invested

Capital invested by funds: $153M → $244M (+$91.4M)

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2.98% more ownership

Funds ownership: 73.98% → 76.96% (+3%)

4% less funds holding

Funds holding: 76 → 73 (-3)

Holders
73
Holders Change
-3
Holders Change %
-3.95%
% of All Funds
1.44%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.1%
New
19
Increased
28
Reduced
14
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.68M
2
Franklin Resources
Franklin Resources
California
+$3.7M
3
Victory Capital Management
Victory Capital Management
Texas
+$3.57M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$2.49M
5
SFM
Sphera Funds Management
Israel
+$1.93M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$10.3M
2
PC
Polar Capital
United Kingdom
-$9.72M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.61M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.01M
5
Neuberger Berman Group
Neuberger Berman Group
New York
-$682K
Name Holding Trade Value Shares
Change 		Change in
Stake
Neuberger Berman Group
76
Neuberger Berman Group
New York
– -$682K -58,812 Closed
SSA
77
Schonfeld Strategic Advisors
New York
– -$471K -40,600 Closed
SCM
78
Stonepine Capital Management
Oregon
– -$383K -33,033 Closed
Renaissance Technologies
79
Renaissance Technologies
New York
– -$221K -19,028 Closed
Swiss National Bank
80
Swiss National Bank
Switzerland
– -$204K -17,600 Closed
TI
81
Trexquant Investment
Connecticut
– -$183K -15,799 Closed
ECM
82
ExodusPoint Capital Management
New York
– -$158K -13,600 Closed
VEA
83
Virtus ETF Advisers
New York
– -$147K -12,688 Closed
Invesco
84
Invesco
Georgia
– -$130K -11,257 Closed
JG
85
Jefferies Group
New York
– -$131K -11,250 Closed
Citadel Advisors
86
Citadel Advisors
Florida
– -$118K -10,194 Closed
TRCT
87
Tower Research Capital (TRC)
New York
– -$45K -3,877 Closed
LC
88
Lindbrook Capital
California
– -$15K -1,250 Closed
CSS
89
Cubist Systematic Strategies
Connecticut
– -$9K -782 Closed
PHK
90
Point72 Hong Kong
Hong Kong
– -$2K -142 Closed
1 2 3
4

KALV Hedge Fund Activity: Q4 2019 in Review

73 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2019, worth a combined $244M — up 60% from $153M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new KALV positions and 17 closed out — a net gain of 2 holders — while 28 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.68M. The largest seller was Deerfield Management, exiting entirely with an estimated $10.3M sold.

  • 73 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2019, down from 76 in Q3 2019.
  • Funds reported $244M of KalVista Pharmaceuticals stock for Q4 2019, up 60% quarter-over-quarter.
  • 19 funds opened new KalVista Pharmaceuticals positions in Q4 2019 and 17 closed out, a net change of +2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $9.68M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2019 was Deerfield Management, an estimated $10.3M sold.

Based on aggregated 13F filings for Q4 2019.